Vancouver, BC and INNSBRUCK, Austria – May 6, 2021 – AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate… Read More
VANCOUVER, BC– NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical-stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased… Read More
THOUSAND OAKS, Calif., May 5, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla® (apremilast) for the treatment of adults… Read More
Human Factors discovery, innovation, and regulatory compliance are crucial to delivering a successful medical device. On May 11th, 2021, 10:00 AM PDT, four human factor experts will present lessons learned,… Read More
Vancouver, BC – May 4th, 2021– AbCellera (Nasdaq: ABCL) today announced that a second antibody from its collaboration with Eli Lilly and Company (Lilly), LY-CoV1404, has entered clinical trials in… Read More
